Replies to post #18526 on GTC Biotherapeutics (fka GTCB)

[biopearl]

Vin, GTCB did say it was not their fault but that of the contractor and was compensated for such. But I would guess that the contract with LEO would have the "buck" stop with GTCB so the responsibility for supply to LEO would still be theirs. It did take LEO forever to get pricing, who knows even where it stands now. It could be that they (LEO) will take the position that lack of supply (from the fill and finish debacle) hindered either pursuit of European pricing or proceding with the DIC study because the drug was not provided in a timely fashion. What else might constitute "cause" even if they were just stonewalling to try to get out of the contract? bp